Introduction: The liver is the main source of serum insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) and the concentration of these proteins might reflect liver function. Methods: In a retrospective longitudinal study we examined serum levels of total and free IGF-I, IGF-II, IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-6 in 21 adult patients with end-stage liver disease before and after orthotopic liver transplantation (LTX) by sensitive and specific RIAs. In each patient, the mean value of at least three measurements before and after LTX was calculated. Results: Before LTX, serum levels of total and free IGF-I, IGF-II, IGFBP-3 were low and showed a rapid and significant increase in almost all patients after successful LTX (total IGF-I: 30 ± 7 vs. 256 ± 30 ng/ml, p < 0.001; free IGF-I: 1.3 ± 0.3 vs. 3.5 ± 0.6 ng/ml, p < 0.01; IGF-II: 177 ± 28 vs. 618 ± 30 ng/ml, p < 0.001; IGFBP-3: 1,230 ± 136 vs. 3,665 ± 264 ng/ml, p < 0.001). In contrast, IGFBP-1 was found to be high immediately before LTX, and declined to normal levels after LTX (210 ± 40 vs. 90 ± 15 ng/ml, p < 0.01), while IGFBP-2 did not show any significant changes (1,154 ± 296 vs. 1,303 ± 192 ng/ ml). Positive correlations were found between IGF-I, IGF-II or IGFBP-3, and serum pseudocholinesterase (R = 0.50, 0.72 and 0.61 respectively, p < 0.001). Negative correlations were found between IGF-I, IGF-II or IGFBP-3, and prothrombin time (R = 0.50, 0.59 and 0.51 respectively, p < 0.001). Conclusion: Patients with severe liver disease show decreased levels of total and free IGF-I, IGF-II and IGFBP-3, and increased levels of IGFBP-1. These abnormalities are promptly normalized after successful LTX. Thus, serum levels of IGF-I, IGF-II and IGFBP-3 might be useful parameters for the assessment of liver function.

Keywords:
Insulin-like growth factors, IGF, Binding proteins, Liver disease, Liver function, Liver transplantation
1.
Blomsma MC, de Knegt RJ, Dullaart RPF, Jansen PLM: Insulin-like growth factor-I in liver cirrhosis. J Hepatol 1997;27:1133–1138.
2.
Moller S, Becker U: Insulin-like growth factor 1 and growth hormone in chronic liver disease. Dig Dis 1992;10:239–248.
3.
Moller S, Gronbaek M, Main K, Becker U, Skakkebaek NE: Urinary growth hormone excretion and serum insulin-like growth factor 1 in patients with alcoholic cirrhosis. J Hepatol 1993;17:315–320.
4.
Quirk P, Owens P, Moyse K, et al: Insulin-like growth factors I and II are reduced in plasma from growth retarded children with chronic liver disease. Growth Regul 1993;4:35–38.
5.
Caufriez A, Reding P, Urbain D, Golstein J, Copinschi G: Insulin-like growth factor I: A good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991;14:317–321.
6.
Kratzsch J, Blum WF, Schenker E, Keller E: Regulation of growth hormone (GH), insulin-like growth factor (IGF)-I, IGF binding proteins-1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Metab 1995;103:285–291.
7.
Moller S, Juul A, Becker U, Flyvbjerg A, Skakkebaek NE, Henriksen JH: Concentrations, release and disposal of insulin-like growth factor (IGF)-binding proteins, IGF-I, and growth hormone in different vascular beds in patients with cirrhosis. J Clin Endocrinol Metab 1995;80:1148–1157.
8.
Donaghy A, Ross R, Gimson A, Hughes SC, Holly J, Williams R: Growth hormone, insulin-like growth factor-1, and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 1995;21:680–688.
9.
Hayakawa T, Kondo T, Shibata T, et al: Serum insulin-like growth factor II in chronic liver disease. Dig Dis Sci 1989;34:338–342.
10.
Scharf JG, Schmitz F, Frystyk J, et al: Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol 1996;25:689–699.
11.
Assy N, Hochberg Z, Amit T, Shenb-Orr Z, Enat R, Baruch Y: Growth hormone-stimulated insulin-like growth factor (IGF)-I and IGF binding protein-3 in liver cirrhosis. J Hepatol 1997;27:796–802.
12.
Assy N, Hochberg Z, Enat R, Baruch Y: Prognostic value of generation of growth hormone-stimulated insulin-like growth factor-I and its binding protein-3 in patients with compensated and decompensated liver cirrhosis. Dig Dis Sci 1998;43:1317–1321.
13.
Shaarawy M, Fikry MA, Massoud BA, Lotfy S: Insulin-like growth factor binding protein-3: A novel biomarker for the assessment of the synthetic capacity of hepatocytes in liver cirrhosis. J Clin Endocrinol Metab 1998;83:3316–3319.
14.
Shen XY, Holt RI, Miell JP, et al: Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors. J Clin Endocrinol Metab 1998;83:2532–2538.
15.
Cuneo RC, Hickman PE, Wallace JD, et al: Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocrinol 1995;43:265–275.
16.
Baruch Y, Amit T, Hertz P, Enat R, Youdim MBH, Hochberg Z: Decreased serum growth hormone-binding protein in patients with liver cirrhosis. J Clin Endocrinol Metab 1991;73:777–780.
17.
Hattori N, Kurahachi H, Ikekubo K, et al: Serum growth hormone-binding protein, insulin-like growth factor-I and growth hormone in patients with liver cirrhosis. Metabolism 1992;41:377–381.
18.
Postel-Vinay MC: Growth hormone- and prolactin-binding proteins: Soluble forms of receptors. Horm Res 1996;45:178–181.
19.
Caregaro L, Alberino F, Amodio P, et al: Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition 1997;13:185–190.
20.
Moller S, Becker U, Juul A, Skakkebaek NE, Christensen E: Prognostic value of insulin-like growth factor I and its binding protein in patients with alcohol-induced liver disease. EMALD group. Hepatology 1996;23:1073–1078.
21.
Assy N, Hochberg Z, Enat R, Baruch Y: Prognostic value of generation of growth hormone-stimulated insulin-like growth factor-I and its binding protein-3 in patients with compensated and decompensated liver cirrhosis. Dig Dis Sci 1998;43:1317–1321.
22.
Pasqualini T, Fainstein-Day P, Gutman R, Balzaretti M, D’Agostino D: Thyroid function and serum IGF-1 in children before and after liver transplantation. J Pediatr Endocrinol 1994;7:343–348.
23.
Sarna S, Sipila I, Vihervuori E, Koistinen R, Holmberg C: Growth delay after liver transplantation in childhood: Studies of underlying mechanisms. Pediatr Res 1995;38:366–372.
24.
Infante D, Torma R, Castro de Kolster C, et al: Changes in growth, growth hormone, and insulin-like growth factor-I after orthotopic liver transplantation. Pediatr Surg Int 1998;13:323–326.
25.
Holt RIG, Jones JS, Stone NM, Baker AJ, Miell JP: Sequential changes in insulin-like growth factor (IGF)-I and IGF-binding proteins in children with end-stage liver disease before and after successful orthotopic liver transplantation. J Clin Endocrinol Metab 1996;81:160–168.
26.
Buzi F, Bontempelli AM, Alberti D, et al: Growth, insulin-like growth factor (IGF)-I, and IGF-binding proteins 1 and 3 in children with severe liver disease before and after liver transplantation: A longitudinal and cross-sectional study. Pediatr Res 1998;43:478–483.
27.
Schalch DS, Kalayoglu M, Pirsch JD, Yang H, Raslich M, Rajpal S: Serum insulin-like growth factors and their binding proteins in patients with hepatic failure and after liver transplantation. Metab 1998;47:200–206.
28.
Koshravi MJ, Diamandi A, Mistry J: Immunoassay of insulin-like growth factor binding protein-1. Clin Chem 1997;43:523–532.
29.
Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J, Juul A: Insulin-like growth factors (IGF-I, free IGF-I, and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal 1999;13:166–172.
30.
Weber MM, Simmler P, Fottner C, Engelhardt D: Insulin-like growth factor (IGF)-II is more potent than IGF-I in stimulating cortisol secretion from cultured bovine adrenocortical cells: Interaction with the IGF-I receptor and IGF-binding proteins. Endocrinology 1995;136:3714–3720.
31.
Holt RI, Crossey PA, Jones JS, Baker AJ, Portmann B, Miell JP: Hepatic growth hormone-receptor, insulin-like growth factor I, and insulin-like growth factor-binding protein messenger RNA expression in pediatric liver disease. Hepatology 1997;26:1600–1606.
32.
Ross RJM, Chew SL, D’Souza Li L, et al: Expression of IGF-I and IGF-binding protein genes in cirrhotic liver. J Endocrinol 1996;149:209–216.
33.
Davies SC, Wass JAH, Ross RJM, et al: The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 1991;130:469–473.
34.
Davenport ML, Isley WL, Pucilowska JB, et al: Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab 1992;75:590–595.
35.
Cotterill AM, Mendel P, Holly JMP, et al: The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery. Clin Endocrinol 1996;44:91–101.
36.
Bang P, Nygren J, Carlsson-Skwirut C, Thorell A, Ljungqvist O: Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: Relation to insulin and insulin sensitivity. J Clin Endocrinol Metab 1998;83:2509–2515.
37.
Ross RJ, Rodriguez-Arnao J, Donaghy A, et al: Expression of IGFBP-1 in normal and cirrhotic human livers. J Endocrinol 1994;141:377–382.
38.
Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H: Insulin resistance in cirrhosis: Prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998;28:141–149.
39.
Shmueli E, Stewart M, Alberti KGMM, Record CO: Growth hormone, insulin-like growth factor-1 and insulin resistance in cirrhosis. Hepatology 1994;19:322–328.
40.
Shmueli E, Miell JP, Stewart M, Alberti KG, Record CO: High insulin-like growth factor binding protein 1 levels in cirrhosis: Link with insulin resistance. Hepatology 1996;24:127–133.
41.
Lee PD, Giudice LC, Conover CA, Powell DR: Insulin-like growth factor binding protein-1:Recent findings and new directions. Proc Soc Exp Biol Med 1997;216:319–357.
42.
Sarin SK, Dhingra N, Bansal A, Malhotra S, Guptan RC: Dietary and nutritional abnormalities in alcoholic liver disease: A comparison with chronic alcoholics without liver disease. Am J Gastroenterol 1997;92:777–783.
43.
Kondrup J, Nielsen K, Juul A: Effect of long-term refeeding on protein metabolism in patients with cirrhosis of the liver. Br J Nutr 1997;77:197–212.
44.
Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis: Nutritional status in cirrhosis. J Hepatol 1994;21:317–325.
45.
Oster MH, Fielder PJ, Levin N, Cronin MJ: Adaptation of the growth hormone and insulin-like growth factor-I axis to chronic and severe calorie or protein malnutrition. J Clin Invest 1995;95:2258–2265.
46.
Clemmons DR: Use of growth hormone and insulin-like growth factor I in catabolism that is induced by negative energy balance. Horm Res 1993;40:62–67.
47.
Jenkins RC, Ross RJ: Growth hormone therapy for protein catabolism. QJM 1996;89:813–819.
48.
Picardi A, de Oliveira AC, Muguerza B, et al: Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol 1997;26:191–202.
49.
Mendenhall CL, Roselle GA, Grossman CJ, Gartside P: The effects of recombinant human insulin-like growth factor-I on nutritional recovery in the malnourished alcoholic rat. I. Alcohol Clin Exp Res 1997;21:1676–1681.
50.
Merli M, Riggio O, Dally L, and PINC (Policentrica Italiana Nutrizione Cirrosi): Does malnutrition affect survival in cirrhosis? Hepatology 1996;23:1041–1046.
51.
Selberg O, Boettcher J, Tusch G, Pichlmayr R, Henkel E, Mueller MJ: Identification of high- and low-risk patients before liver transplantation: A prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997;25:652–657.
52.
Moller S, Bexker U, Gronbaek M, Juul, Winkler K, Skakkebaek NE: Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. J Hepatol 1994;21:710–717.
53.
Donaghy A, Ross R, Wicks C, et al: Growth hormone therapy in patients with cirrhosis: A pilot study of efficacy and safety. Gastroenterology 1997;113:1617–1622.
54.
Gianotti L, Broglio F, Aimaretti G, et al: Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions. J Endocrinol Invest 1998;21:115–121.
55.
Castilla-Cortazar I, Garcia M, Muguerza B, et al: Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 1997;113:1682–1691.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.